CLDN1 and inflammatory bowel disease: These effects collectively attenuated mucosal inflammation, reduced proinflammatory cytokine production (e.g., TNF-α, IL-6, IL-1β), and preserved tight junction protein expression (ZO-1 and Claudin 1), highlighting Eng as a multitargeted therapeutic candidate for IBD.